ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

House Reprogramming Of NCI Funds Analyzed; Community Programs Would Be Hurt

July 13, 1979

Holden Center At U. Of Iowa Designated Comprehensive.

January 26, 2001

More Than 3,000 Letters If Intent Sent To army For Breast Programs

September 10, 1993

Low-Dose IFN Not Effective Against Melanoma, Study Finds

December 26, 2003

In Brief: Ronald Levy, George Stevenson To Share First Hammer Prize; President Reappoints Hammer

December 3, 1982

Afinitor Approved for Rare Disorder

November 5, 2010